Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
Jul 1 AMGN 10 clinical trials to watch in the second half of 2024
Jun 29 AMGN How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth?
Jun 29 SNY Where Will Novavax Be in 1 Year?
Jun 29 AMGN 1 Dividend Growth Stock to Buy and Hold for 10 Years
Jun 29 XOMA XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Jun 28 XOMA XOMA Corporation's (NASDAQ:XOMA) institutional investors lost 11% last week but have benefitted from longer-term gains
Jun 28 SNY PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Jun 28 SNY 3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
Jun 27 MYGN Myriad Genetics started at sector outperform at Scotiabank on addressable markets
Jun 27 EXEL The 23% return delivered to Exelixis' (NASDAQ:EXEL) shareholders actually lagged YoY earnings growth
Jun 27 LNTH Lantheus acquires global rights to Life Molecular's drug for prostate and breast cancers
Jun 27 LNTH Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
Jun 27 SNY Vigil Neuroscience jumps 34% as Sanofi invests $40M
Jun 27 SNY Formation Bio secures $372m funds for AI-driven drug platform
Jun 27 AMGN Can Amgen Stock Keep Trouncing the S&P 500?
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags